MedTrace Logo

Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function

NCT00693069 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-08-21

No results posted yet for this study

Summary

Adequate platelet inhibition before percutaneous coronary intervention (PCI) reduces peri-procedural and long-term ischemic complications. Documented reduced response to clopidogrel has been associated with subsequent major adverse cardiovascular events. Strategies to optimize platelet inhibition pre-PCI are under investigation.

This study sought to evaluate the effect on platelet aggregation of four different dosing regimens of clopidogrel given before elective PCI.

Conditions

Interventions

DRUG

Clopidogrel

clopidogrel 300 mg on the day prior to angiography

DRUG

Clopidogrel

clopidogrel 600 mg on the day prior to angiography

DRUG

Clopidogrel

clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography

DRUG

Clopidogrel

clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography

Sponsors & Collaborators

  • Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

    lead OTHER

Principal Investigators

  • Jean G Diodati, MD · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2006-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00693069 on ClinicalTrials.gov